ABF Ingredients (ABFI, U.K.) has acquired Fytexia Group, a life science company developing scientifically supported active nutrients for dietary supplements. This strategic acquisition will expand ABFI’s portfolio of products and capabilities to better serve the pharmaceutical, nutritional and food market sectors.

Headquartered in France, with a presence in Europe and regional offices in the U.S. and Asia, Fytexia Group is ideally positioned to serve customers globally, the company stated. Fytexia Group focuses on the research and scientific validation of bioactive compounds to deliver functional ingredients for the improvement of human health and well-being, targeting non-communicable diseases. Fytexia Group is comprised of two businesses, Fytexia, a global expert in polyphenols, and B Natural, the European leader for the extraction and refinement of brown propolis.

“Fytexia Group is a strong science driven business with a successful track record servicing the dietary supplements industry,” said Fabienne Saadane-Oaks, CEO of ABFI. “Fytexia Group will make an excellent addition to our family of businesses by bringing expertise in polyphenols and health and nutrition active ingredients extracts from botanicals and propolis, therefore strengthening the ABFI offering in health and nutrition ingredients.”

“We are very excited to join ABFI. We share the same values and are both convinced that natural science based nutritional solutions are the future of the industry,” added Matthieu Arguillère, CEO of Fytexia Group. “At Fytexia Group, we believe ABFI is the perfect partner to accelerate the development of our activity globally in the best possible conditions, with the support of a larger organization. Therefore, we will accelerate our clinical research to support our existing product line as well as our future developments.”

“Fytexia Group has demonstrated over the last few years an outstanding track record of growth, driven by strong investments in science and product development, and international expansion, under the majority ownership of ArchiMed. The company is now a recognized category leader in polyphenols, which are a strategic class of molecules for nutraceuticals, with proven metabolic and physiological properties and increasing scientific traction. It has been a real pleasure working closely with Matthieu Arguillère and his team to accelerate the development of Fytexia Group through a buy-and-build strategy. We have been convinced by the strategic plan shared between ABFI and the management team and we wish them a great success for this new venture,” ArchiMed Partner, Robin Filmer-Wilson, commented.

For more information, visit www.abfingredients.com/en/.